Department of Community and Economic Development Secretary (DCED) Rick Siger celebrated plans by global health care company Johnson & Johnson to continue investing in Pennsylvania. The company plans to build a next generation cell therapy manufacturing site in Pennsylvania.
“Pennsylvania is a national leader in the biotech and life sciences industry, offering companies a strategic location, world-class research infrastructure, and a highly skilled workforce,” said Secretary Siger.
The global health care company is focused on Innovative Medicine and MedTech solutions, guided by its purpose to profoundly impact health for humanity. Johnson & Johnson, which employs over 138,000 people worldwide, employs thousands of highly skilled people at numerous sites in Pennsylvania, including research and development, and manufacturing facilities.
“Our investment in a next generation cell therapy manufacturing facility in Pennsylvania builds on Johnson & Johnson’s 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The new facility will increase our already significant footprint in the Commonwealth, adding U.S.-based jobs to manufacture cutting edge medicines for patients.”
